Results 101 to 110 of about 197,741 (365)

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine

Vaccines, 2022
We evaluated the immune response against the Omicron variant after mRNA-based COVID-19 booster vaccination in medical students. We prospectively enrolled medical students who received two primary doses of the mRNA-1273 vaccine.
Hyemin Chung, Jongsung Lee, Kyungrok Minn, Jiyoung Lee, Soyoung Yun, Joung Ha Park, Min-Chul Kim, Seong-Ho Choi, Jin-Won Chung   +8 more
doaj   +1 more source

Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters

Journal of Virology, 2022
Waning vaccine-induced immunity coupled with the emergence of SARS-CoV-2 variants has led to increases in breakthrough infections, prompting consideration for vaccine booster doses. Boosters have been reported to be safe and increase SARS-CoV-2-specific neutralizing antibody levels, but how these doses impact the trajectory of the global pandemic and ...
Rachel M. Burckhardt, John J. Dennehy, Leo L. M. Poon, Linda J. Saif, Lynn W. Enquist   +4 more
openaire   +3 more sources

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Journal of Infectious Diseases
Background An mRNA-based respiratory syncytial virus (RSV) vaccine, mRNA-1345, is under clinical investigation to address RSV disease burden in older adults.
Christine A. Shaw, B. Essink, Charles Harper, Runa Mithani, Archana Kapoor, Rakesh Dhar, Lauren Wilson, Ruiting Guo, C. Panozzo, E. Wilson, Alana K. Simorellis, Caroline Reuter, S. Stoszek, Grace L Chen, R. Das, Jaya Goswami   +15 more
semanticscholar   +1 more source

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

MMWR. Morbidity and mortality weekly report, 2022
During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered ...
Anne M. Hause, J. Baggs, P. Marquez, T. Myers, John R. Su, P. Blanc, Jane A Gwira Baumblatt, E. Woo, J. Gee, T. Shimabukuro, D. Shay   +10 more
semanticscholar   +1 more source

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

BOOSTER: Development of a toolbox for triage of large groups of individuals exposed to radioactive material

, 2014
International audienceThe effective management of an event involving the exposure of a large number of people to radioactive material requires a mechanism for fast triage of exposed people.
Mesterhazy, David, Becker, Frank, Raskob, Wolfgang, Kelemen, Andras, Morat, Luc, Gaboriau, David, Menaa, Nabil, Szabó, Sándor, Ugolin, Nicolas, Morrison, Ciaran, Carrel, Frédérick, Kovacs-Szeles, Eva, Gmar, Mehdi, Almasi, Istvan, Vincze, Arpad, Amgarou, Khalil, Schoepff, Vincent, Trybushnyi, Dmytro, Lemaire, Hermine, Perez-Llopis, Israel, Testard, Isabelle, Viau, Muriel, Carvajal, Federico, Kovacs, Andras, Robbe, Marie-France   +24 more
core   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Using cluster analysis to explore COVID-19 vaccine booster hesitancy by levels of medical mistrust in fully vaccinated US adults

Annals of Medicine
Background Underlying causes of vaccine hesitancy could significantly affect successful uptake of the SARS-CoV2 vaccine booster doses during new waves of COVID-19.
Kirsten Paulus, Sarah Bauerle Bass, Whitney Cabey, Katie Singley, Caseem Luck, Ariel Hoadley, Molly Kerstetter, Alexandru-Mircea Rotaru, Elizabeth Knight, Swathi Murali, Shreya Verma, Imani Wilson-Shabazz, Heather Gardiner   +12 more
doaj   +1 more source

Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States

Nature Communications
The optimal frequency of COVID-19 booster vaccination is unclear. Here, the authors use a microsimulation model to assess the impact of different vaccine schedules on severe disease and show that regular boosters have large benefits for older and ...
Hailey J. Park, G. Gonsalves, S. Tan, J. Kelly, George W. Rutherford, Robert M. Wachter, R. Schechter, A. D. Paltiel, Nathan C. Lo   +8 more
semanticscholar   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source